Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease
Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease
Vedolizumab in early and late Crohn’s disease (LOVE-CD): a phase 4 open-label cohort study
Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn’s disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial